The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Immune checkpoint blockade therapies, particularly targeting programmed cell death protein 1 (PD-1), have revolutionized cancer treatment.
• These therapies harness the immune system to fight cancer but are associated with immune-related adverse events (irAEs), highlighting the critical role of immune checkpoints in maintaining self-tolerance.

Purpose of the Study:

• To elucidate the mechanisms by which programmed cell death protein 1 (PD-1) regulates T cell responses, with a specific focus on its role in suppressing regulatory T cell function.
• To review the clinical successes and limitations of checkpoint blockade immunotherapy.
• To analyze the clinical and mechanistic characteristics of irAEs and explore strategies for modulating PD-1 blockade to improve therapeutic outcomes.

Main Methods:

• Review of existing literature on PD-1 function, checkpoint blockade immunotherapy, and irAEs.
• Analysis of clinical data and mechanistic studies related to PD-1 signaling in T cells and regulatory T cells.
• Exploration of potential therapeutic strategies for optimizing PD-1 blockade.

Main Results:

• PD-1 plays a crucial role in controlling T cell responses, notably by restraining regulatory T cell activity.
• Checkpoint blockade immunotherapy demonstrates significant efficacy in various cancers but is linked to irAEs.
• Understanding the interplay between PD-1, T cells, and autoimmunity is key to refining these therapies.

Conclusions:

• Modulating PD-1 blockade offers a promising avenue to enhance anti-tumor immunity while mitigating the risk of autoimmune side effects.
• Further research into PD-1's regulatory functions is essential for developing safer and more effective cancer immunotherapies.